“Genedata Biologics allows us to digitalize our work, increasing quality and efficiency of our antibody discovery and protein production by integrating processes and connecting our global operations,”said Katherine Vousden, Ph.D., Head of Large Molecule Discovery, Charles River
BASEL, Switzerland (PRWEB)
February 08, 2022
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Charles River Laboratories International, Inc., has chosen Genedata Biologics® to support their rapidly expanding global biopharma operations across multiple groups in the UK and the USA.
“Reducing project timelines within the discovery of new therapeutics is critical for both us and our clients,” said Katherine Vousden, Ph.D., Head of Large Molecule Discovery, Charles River. “Genedata Biologics allows us to digitalize our work, increasing quality and efficiency of our antibody discovery and protein production by integrating processes and connecting our global operations. Our partners and clients who also use the platform will see the benefit of easier information sharing.”
Charles River Discovery is using Genedata Biologics as their central data backbone across antibody discovery and protein production, including the recently acquired Distributed Bio and their proprietary AbGenesis antibody technology. Genedata will help accelerate internal data transfer and reduce operational bottlenecks so their clients can more quickly achieve critical development goals from discovery to commercialization. Genedata Biologics supports the full breadth of Charles RiverDiscovery’s processes, including antigen generation, immuno-engineering, antibody repertoire sequencing, TCR repertoire analysis, and specialized functional assays, allowing them to systematically track, analyze, and optimize thousands of antibody repertoires and antibody libraries. Charles River has been using Genedata Screener R&D for many years and is now expanding usage of Genedata to their biotherapeutic discovery groups.
“We are delighted that Charles River, one of the leading partners to the biopharmaceutical industry worldwide, has decided to embark on Genedata Biologics,” said Othmar Pfannes, Ph.D., CEO of Genedata. “It’s exciting that more and more companies offering drug discovery as a service are adopting Genedata Biologics to support biopharma R&D, including for cell & gene therapies. This demonstrates the flexibility and scalability of our platform and how it supports seamless access and transfer of data between CROs and CDMOs and their biopharma and biotech partners. Our vision is to provide a global, shared digital backbone for the biopharmaceutical industry, which will help them bring innovative medicines to the patients sooner.”
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn | Twitter | YouTube
________________________________________
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Share article on social media or email: